Delivered by QUT, the Bridge Program involves a consortium of pharmaceutical companies, universities and industry affiliates. Launched in 2017, the program selects 100 participants annually from across Australia to take part in face-to-face and online training in the various disciplines that contribute to the commercialisation of new medicines. The tacit industry knowledge that the Bridge Program consortium provides makes the program unique in its integration into venture capital and global pharmaceutical networks and its ability to share specific, detailed and practical know-how.

The Bridge Program was awarded industry matched funding through both MTPConnect’s Project Fund Program, the Biomedical Translation Bridge Program, and now MTPConnect’s Researcher Exchange and Development within Industry (REDI) initiative. It is an exciting education program that provides the training needed to successfully commercialise Australian pharmaceutical research. Learn more at the MTPConnect website.

Each year up to 100 people from a diverse range of professions and institutions around Australia are selected to join the Bridge Program, delivered by QUT. Fully funded by MTPConnect and a consortium of industry and university partners, Bridge Program participants join one of the country’s most significant pharmaceutical and biotech professional networks.

The program will helps researchers gain confidence and create networks and opportunities in all areas of pharmaceutical research commercialisation. You’ll learn through online modules, attend an inspiring seminar series, and network with top pharma companies and a nation-wide professional community.